The first Project Meeting for the ELIMOX Consortium was held on the 4-5th February 2014 at Krusenbergs Herrgård, Uppsala, Sweden.
Representatives from all 3 SME participants (OxThera AB, Cobra Biologics Ltd and SymbioPharm GmbH) and the majority of the RTDP research institutions (Ergomed, Universitätsklinikum Bonn (UKB), Hospices Civils de Lyon (HCL), University College London Hospitals (UCLH), Galenica AB, Institut für Mikroökologie and Bio-Images Research Ltd) attended the meeting. 2 RTDPs (KABS Pharmaceutical and TNO) were unfortunately unable to come to the meeting.
All attendees presented an update on their roles and activities in the ELIMOX project. Discussions focused on the 5 Work Packages (WP) within the project, namely:
• WP 1: Project Management
• WP2: Development of Drug Product Intermediate and Drug Product
• WP3: Development of analytical tools for development and drug delivery of Oxalobacter formigenes therapy
• WP4 . Clinical studies of Oxalobacter formigenes
• WP5: Dissemination and Exploitation of project results
The focus of this meeting was a technical update of the ELIMOX activities and the current status of these. This meeting followed the Kick-Off meeting held on 19 September 2013 in Frankfurt which focused on the administrative aspects of the study. Information on the project deliverables and milestones was also provided.